Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606086 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
A Phase 2 study, sponsored by GlobeImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00606086 is a Phase 2 study that has completed, run by GlobeImmune. The registered enrollment target is 140 participants.
The verdict
NCT00606086, a Phase 2 study, has completed, sponsored by GlobeImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.
Interventions
- DRUG GI-5005
- DRUG Pegylated Interferon and Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2007-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606086
The ClinicalTrials.gov registry entry for NCT00606086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlobeImmune, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GI-5005 is the first listed.
NCT00606086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606086 about?
NCT00606086 is a clinical study titled "Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection". The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections including EVR, ETR, and SVR.
What is the current status of trial NCT00606086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2007-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00606086?
The interventions under investigation include: GI-5005 (DRUG), Pegylated Interferon and Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00606086?
This trial is sponsored by GlobeImmune, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.